Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q4 FY21 results · Jan–Mar 2021
Bliss GVS Pharma reported revenue from operations of ₹132.05 crore (up 10.2% from Q4 FY20) and net profit of ₹8.15 crore (up 46.3% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 132.05 | 119.80 | +10.2% | 164.06 | −19.5% |
| Other income | 6.33 | 16.60 | −61.9% | 4.12 | +53.7% |
| Total income | 138.38 | 136.40 | +1.5% | 168.18 | −17.7% |
| Profit before tax | 16.58 | 13.33 | +24.4% | 37.09 | −55.3% |
| Net profit for the period | 8.15 | 5.57 | +46.3% | 27.56 | −70.4% |
| Attributable to shareholders of the company | 6.24 | 8.75 | −28.6% | 25.55 | −75.6% |
| EPS, basic (₹) | 0.61 | 0.85 | −28.2% | 2.48 | −75.4% |
| Net margin (%) | 6.2 | 4.7 | 16.8 |
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 105.23 | 97.97 | +7.4% | 127.44 | −17.4% |
| Other income | 4.30 | 15.24 | −71.8% | 3.25 | +32.1% |
| Total income | 109.53 | 113.21 | −3.2% | 130.69 | −16.2% |
| Profit before tax | 14.07 | 23.53 | −40.2% | 30.44 | −53.8% |
| Net profit for the period | 9.16 | 16.42 | −44.2% | 22.46 | −59.2% |
| EPS, basic (₹) | 0.89 | 1.59 | −44.0% | 2.18 | −59.2% |
| Net margin (%) | 8.7 | 16.8 | 17.6 |
Consolidated
- Filed with BSE
- 13 May 2021, 15:55 IST
- Board meeting
- 11 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 May 2021, 15:55 IST
- Board meeting
- 11 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE